teaser
The Committee for Medicine Products for Human Use (CHMP) has refused, on re-examination of Allos Therapeutics Limited’s application, to recommend marketing authorisation for Folotyn (pralatrexate) for treatment of peripheral T-cell lymphoma.
This follows its adoption of a negative opinion on 19 January 2012, when it recommended refusal of marketing authorisation for Folotyn for peripheral T-cell lymphoma.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Folotyn contains the active substance pralatrexate, and it was intended to be available as a solution for infusion.
Folotyn was designated an ‘orphan medicine’, for use in rare diseases, 13 April 2007.
